Organon & Co.

OGN

US68622V1061

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
18.55 ^USD	+0.71%		+4.10%	+28.64%

Apr. 09	Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	MT
Apr. 08	Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	MT

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

December 05, 2023 at 04:31 pm EST

On December 5, 2023, Organon & Co. announced that Dr. Sandra Milligan will be departing from the Company on January 5, 2024. Effective December 1, 2023, Dr. Milligan ceased performing her functions as Head of Research and Development, and she will serve as a senior advisor to the Company until her departure on January 5, 2024.

Latest news about Organon & Co.

Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	Apr. 09	MT
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	Apr. 08	MT
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	Mar. 19	MT
Philips: new CFO in October	Feb. 28	CF
New York attorney general urges stronger safety warning on asthma drug Singulair	Feb. 23	RE
Organon's Hadlima Chosen by VA as Substitute for Humira	Feb. 20	MT
Goldman Sachs Adjusts Price Target on Organon to $18 From $16, Keeps Neutral Rating	Feb. 20	MT
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	Feb. 20	CI
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	Feb. 20	CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	Feb. 15	MT
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	Feb. 15	MT
Transcript : Organon & Co., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B	Feb. 15	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q4 EPS $0.88, vs. Street Est of $0.83	Feb. 15	MT
Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024	Feb. 15	CI
Organon & Co. Provides Earnings Guidance for the Year 2024	Feb. 15	CI
Organon Says Xaciato Vaginal Gel 2% Now Available in the US via Prescription to Treat Bacterial Vaginosis	Jan. 10	MT
Organon?S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older	Jan. 10	CI
Transcript : Organon & Co. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM	Jan. 09
Organon Affirms 2023 Revenue Outlook, Sets 2024 Guidance; Shares Jump	Jan. 08	MT
Organon Signs Agreement With Eli Lilly to Distribute, Market Two Migraine Medicines in Europe	Dec. 18	MT
Organon & Co. and Eli Lilly and Company Enter Commercialization Agreement in Europe for Two Migraine Medicines	Dec. 18	CI
Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024	Dec. 05	CI
Transcript : Organon & Co. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 11:00 AM	Nov. 29

Chart Organon & Co.

Duration

Period

More charts

Company Profile

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Companyâs Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Sector

Pharmaceuticals

Calendar

2024-05-02 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Organon & Co.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

18.55 USD

Average target price

21.5 USD

Spread / Average Target

+15.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORGANON & CO.	+28.64%	4.77B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+26.14%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+14.55%	231B
NOVARTIS AG	+5.28%	200B
ROCHE HOLDING AG	-8.92%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Organon & Co.

Equities

OGN

US68622V1061

Pharmaceuticals

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

EPS Revisions